Burnet Institute is a collaborator in an important new study exploring the short and long-term impact of the COVID-19 pandemic on the experiences of Australians who use illicit drugs.
The Australians' Drug Use: Adapting to Pandemic Threats (ADAPT) Study is one of the first studies globally to talk with people who use illicit drugs about the changes they are experiencing in relation to their drug use, harms, and other challenges and positives they may be experiencing.
“We’re trying to capture the breadth of people across the country who use drugs and get a sense from them as to what sort of impacts they are experiencing,” Professor Paul Dietze, Burnet Institute Director, Behaviours and Health Risks, and ADAPT Study Investigator, said.
“We’re doing it in a systematic way and we’ll be following people up initially for the next year, but also possibly for a number of years to see what sort of long term impacts COVID-19 and COVID-19 restrictions have on people.”
The researchers are aiming to share findings quickly to ensure drug-related issues during COVID-19 are better understood, more accurately represented, and used to inform drug treatment and harm reduction in Australia.
This study is being led by researchers from the National Drug and Alcohol Research Centre (UNSW Sydney) in collaboration with Kirby Institute (UNSW Sydney), University of Tasmania, RMIT University, St Vincent’s Hospital, Burnet Institute, The University of Queensland and Flinders University.
Find out more from the ADAPT Study website.